FDA Extends Denecimig Review; US Launch Slips to H1 2027
NVO is trading near its 52-week low of $35.12 (5.0% above the low).
Summary
Novo Nordisk's denecimig US launch is delayed to H1 2027 after the FDA extended its BLA review due to facility remediation issues; no clinical data deficiencies were identified. Shares fell 1.17% to $36.88 on the news.
Updated with a Benzinga report · What changed
Updates
· Benzinga — Novo Nordisk shares fell 1.17% to $36.88 on Monday following the FDA's extension of the denecimig review.
- Regulatory Status — Novo Nordisk submitted the Biologics License Application in September 2025. Denecimig is also undergoing reviews by other international regulatory authorities.
- Facility Impact — The facility feedback does not affect other marketed products.
- Clinical Foundation — Data from FRONTIER2, FRONTIER3, and FRONTIER4 formed the foundation for the Marketing Authorization Application.
- Company Response — Mike Doustdar, president and CEO of Novo Nordisk, said the company is addressing agency requests as efficiently as possible while working closely with regulators to make better care something patients can count on.
All 5 details
- Mike Doustdar, president and CEO of Novo Nordisk, said the company is addressing agency requests as efficiently as possible while working closely with regulators to make better care something patients can count on.
- Novo Nordisk submitted the Biologics License Application in September 2025.
- The facility feedback does not affect other marketed products.
- Denecimig is also undergoing reviews by other international regulatory authorities.
- Data from FRONTIER2, FRONTIER3, and FRONTIER4 formed the foundation for the Marketing Authorization Application.
Key Events · Product Development and Regulatory · NVO
-
New · · Benzinga
Shares Fall on FDA Extension
Novo Nordisk shares fell 1.17% to $36.88 on Monday following the FDA's extension of the denecimig review.
-
New · · Benzinga
CEO Comments on Agency Requests
Mike Doustdar, president and CEO of Novo Nordisk, said the company is addressing agency requests as efficiently as possible while working closely with regulators to make better care something patients can count on.
-
New · · Benzinga
BLA Submitted September 2025
Novo Nordisk submitted the Biologics License Application for denecimig in September 2025.
-
New · · Benzinga
Other International Reviews Underway
Denecimig is also undergoing reviews by other international regulatory authorities.
-
New · · Benzinga
FRONTIER Trials Support Application
Data from FRONTIER2, FRONTIER3, and FRONTIER4 formed the foundation for the Marketing Authorization Application.
-
Updated · · Benzinga
FDA Extends Denecimig BLA Review
The FDA informed Novo Nordisk that the BLA review for denecimig in haemophilia A is still ongoing due to facility remediation activities, with no new timeline for regulatory action. The facility feedback does not affect other marketed products.
-
US Launch Delayed to H1 2027
Novo now aims to launch denecimig in the US in the first half of 2027, versus the previously anticipated Q3 2026 regulatory decision and Q4 2026 launch.
-
No Clinical Data Deficiencies
The FDA has not identified any deficiencies related to the clinical efficacy or safety data submitted in the denecimig BLA.
-
2026 Financial Outlook Unchanged
Novo Nordisk stated the extended FDA review time has no impact on its financial outlook for 2026.
Analysis · NVO · Life Sciences
The FDA has extended its review of Novo Nordisk's denecimig BLA for haemophilia A due to manufacturing facility remediation issues, with no new decision timeline. The delay pushes the anticipated US launch from Q4 2026 to the first half of 2027. Importantly, the FDA found no deficiencies in the clinical efficacy or safety data, and Novo states the delay does not affect its 2026 financial outlook. The setback is operational rather than scientific, but it postpones a key near-term revenue catalyst for the haemophilia franchise. Shares fell 1.17% to $36.88 on Monday following the extension, and the company is addressing agency requests as efficiently as possible while working closely with regulators.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 37.9% of the 895 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.87%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NVO was trading at $36.88 on NYSE in the Life Sciences sector, with a market capitalization of approximately $165.5B. The 52-week trading range was $35.12 to $64.16. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.